ロード中...
Acquired resistance to EGFR‐targeted therapies in colorectal cancer
Cetuximab and panitumumab are anti‐epidermal growth factor receptor (anti‐EGFR) monoclonal antibodies used as therapies for metastatic colorectal cancer patients. Intrinsic mechanisms of resistance, such as RAS mutations, can prevent patients from having a response with clinical benefit. The clinica...
保存先:
| 出版年: | Mol Oncol |
|---|---|
| 主要な著者: | , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
John Wiley and Sons Inc.
2014
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5528615/ https://ncbi.nlm.nih.gov/pubmed/24913799 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.molonc.2014.05.003 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|